{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:27:28Z","timestamp":1787113648995,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006599","name":"Focused Ultrasound Foundation","doi-asserted-by":"publisher","award":["FUS920"],"award-info":[{"award-number":["FUS920"]}],"id":[{"id":"10.13039\/100006599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007334","name":"Ministry of Health and Family Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019266","name":"Korea Medical Device Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["RS-2020-KD000009"],"award-info":[{"award-number":["RS-2020-KD000009"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["2710037285"],"award-info":[{"award-number":["2710037285"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejca.2026.116903","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T22:25:02Z","timestamp":1781994302000},"page":"116903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Non-thermal focused ultrasound with FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer: An explorative phase II trial"],"prefix":"10.1016","volume":"244","author":[{"given":"Dong Ho","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6946-6042","authenticated-orcid":false,"given":"Jae Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8192-0273","authenticated-orcid":false,"given":"Soo Yeon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyub","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8708-3280","authenticated-orcid":false,"given":"Woo Hyun","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Rae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooil","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Young","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116903_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study","volume":"15","author":"De Angelis","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116903_bib2","first-page":"7","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2026.116903_bib3","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1007\/s00330-023-09584-2","article-title":"High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study","volume":"33","author":"Lee","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ejca.2026.116903_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/SLA.0b013e3180691579","article-title":"National failure to operate on early stage pancreatic cancer","volume":"246","author":"Bilimoria","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2026.116903_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2026.116903_bib6","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1007\/s00330-022-09271-8","article-title":"Combination of chemotherapy and focused ultrasound for the treatment of unresectable pancreatic cancer: a proof-of-concept study","volume":"33","author":"Lee","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ejca.2026.116903_bib7","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s10434-001-0758-1","article-title":"Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas","volume":"8","author":"White","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116903_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2026.116903_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2026.116903_bib10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/MPA.0000000000000314","article-title":"FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies","volume":"44","author":"Petrelli","year":"2015","journal-title":"Pancreas"},{"key":"10.1016\/j.ejca.2026.116903_bib11","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jamasurg.2020.2286","article-title":"Response and survival associated with first-line FOLFIRINOX vs Gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma","volume":"155","author":"Perri","year":"2020","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejca.2026.116903_bib12","article-title":"Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer","volume":"100","author":"Chen","year":"2021","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.ejca.2026.116903_bib13","first-page":"84","article-title":"Retrospective analysis of high intensity focused ultrasound combined with S-1 in the treatment of metastatic pancreatic cancer after failure of gemcitabine","volume":"6","author":"Li","year":"2016","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ejca.2026.116903_bib14","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/02656736.2021.1962550","article-title":"Systematic review and trial sequential analysis of high-intensity focused ultrasound combined with chemotherapy versus chemotherapy in the treatment of unresectable pancreatic ductal adenocarcinoma","volume":"38","author":"Guo","year":"2021","journal-title":"Int J Hyperth"},{"key":"10.1016\/j.ejca.2026.116903_bib15","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.3390\/curroncol28060409","article-title":"Novel therapeutic method for unresectable pancreatic cancer-the impact of the long-term research in therapeutic effect of high-intensity focused ultrasound (HIFU) therapy","volume":"28","author":"Sofuni","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ejca.2026.116903_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1148\/radiol.2342030889","article-title":"Delivery of systemic chemotherapeutic agent to tumors by using focused ultrasound: study in a murine model","volume":"234","author":"Yuh","year":"2005","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2026.116903_bib17","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1158\/1078-0432.CCR-06-2443","article-title":"Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect","volume":"13","author":"Dromi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116903_bib18","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.ultrasmedbio.2013.06.004","article-title":"Pulsed high-intensity focused ultrasound enhances apoptosis of pancreatic cancer xenograft with gemcitabine","volume":"39","author":"Lee","year":"2013","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.ejca.2026.116903_bib19","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1158\/0008-5472.CAN-15-0296","article-title":"Pulsed high-intensity focused ultrasound enhances delivery of doxorubicin in a preclinical model of pancreatic cancer","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116903_bib20","first-page":"779","article-title":"Therapeutic effects of microbubbles added to combined high-intensity focused ultrasound and chemotherapy in a pancreatic cancer xenograft model","volume":"17","author":"Yu","year":"2016","journal-title":"kjr"},{"key":"10.1016\/j.ejca.2026.116903_bib21","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1007\/s00330-018-5355-9","article-title":"vivo study of enhanced chemotherapy combined with ultrasound image-guided focused ultrasound (USgFUS) treatment for pancreatic cancer in a xenograft mouse model","volume":"28","author":"Park","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ejca.2026.116903_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5009\/gnl19182","article-title":"Prognostic factors for patients with borderline resectable or locally advanced pancreatic cancer receiving neoadjuvant FOLFIRINOX","volume":"15","author":"Choi","year":"2021","journal-title":"Gut Liver"},{"key":"10.1016\/j.ejca.2026.116903_bib23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/SLA.0000000000001731","article-title":"Pancreatic cancer surgery: the new R-status counts","volume":"265","author":"Strobel","year":"2017","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2026.116903_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41379-020-00683-9","article-title":"Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy","volume":"34","author":"Janssen","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejca.2026.116903_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920953294","article-title":"FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma","volume":"12","author":"Yoo","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2026.116903_bib26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1148\/radiol.2482071674","article-title":"Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib","volume":"248","author":"Poff","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2026.116903_bib27","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116903_bib28","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djz073","article-title":"Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis","volume":"111","author":"Janssen","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.116903_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013592","article-title":"Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience","volume":"97","author":"Lee","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.ejca.2026.116903_bib30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pan.2019.01.001","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan","volume":"19","author":"Matsumoto","year":"2019","journal-title":"Pancreatology"},{"key":"10.1016\/j.ejca.2026.116903_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","article-title":"A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)","volume":"181","author":"Ozaka","year":"2023","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:15:35Z","timestamp":1787112935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S0959804926006842"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116903","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-thermal focused ultrasound with FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer: An explorative phase II trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116903"}}